|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010674,
umls-concept:C0010762,
umls-concept:C0013227,
umls-concept:C0025519,
umls-concept:C0043031,
umls-concept:C0332257,
umls-concept:C0441655,
umls-concept:C0534137,
umls-concept:C0597298,
umls-concept:C0743223,
umls-concept:C1314939,
umls-concept:C1515655,
umls-concept:C2349975
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1994-6-14
|
|
pubmed:abstractText |
To determine whether the activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin is enhanced in cystic fibrosis.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
528-34
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis.
|
|
pubmed:affiliation |
Department of Pharmaceutics, University of Washington, Seattle 98195.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
